

Test Description

The MolQ BRCA Germline mutation test helps assess your risk of developing cancer by detecting a potentially harmful change (mutation) in BRCA1 and BRCA2 genes.

Clinician

Clinician Name: Dr Amit Verma
 Medical Facility: Dr AV Institute of Personalized Therapy and Cancer Research (IPTCR)
 Pathologist: Not Provided

Patient Demographic

Name: Ms Nagwa Ashri Mohamed Hussien
 Sex: Female
 Date of Birth/Age: 60 years
 Disease: High Grade Papillary Serous Carcinoma of Ovary

Specimen

Booking ID: 012109170159
 Site: NA
 Sample Type: Blood
 Date of Collection: 17-09-2021
 Date of Booking: 17-09-2021

CLINICAL SYNOPSIS

Ms. Nagwa Ashri Mohamed Hussien’s Morphology and immunoprofile favors high grade papillary serous carcinoma of ovary. Tumor cells are immunoreactive for ER, WT-1 and CK7 (as per the histopathological report dated 14-04-2021 provided along with Test Requisition Form). The tumor was identifiable in the FFPE block (H-1974/21 A). The NGS data analysis of this patient has identified a variation in BRCA2 gene and the same variation is being validated by Sanger sequencing.

RESULTS

Variant is confirmed to be present by Sanger sequencing.


Analysis For: Variation in BRCA2 Gene		Gene Name: BRCA2 (Exon 3)
S.No.	Variation Detected in NGS	Sanger Validation Result
1.	chr13:g.32893302del; c.156del; p.His52GlnfsTer28	Present (Heterozygous)

*The variant analysis in Sanger sequencing is based on the BRCA2 reference sequence ENST00000544455.1¹. The exon number and nucleotide numbers will differ based on the reference file chosen and the database used.

CLINICAL CORRELATION AND VARIANT INTERPRETATION

Variant description: A frameshift deletion in exon 3 of the BRCA2 gene (**chr13:g.32893302del; c.156del**) that results in a premature truncation of the protein 28 amino acids downstream to codon 52 (**p.His52GlnfsTer28**) was detected in Ms. Nagwa Ashri Mohamed Hussien by NGS.

The same variation was detected in heterozygous condition in this patient by Sanger sequencing (Figure 1)



Jatinder Kaur, PhD
 Head, Molecular Biology & Genomics



Dr. Gulshan Yadav, MD
 Head, Pathology

APPENDIX 1: TEST METHODOLOGY

Method

Targeted gene Sanger sequencing: Exon 3 of the *BRCA2* gene was PCR-amplified and the products were sequenced using Sanger sequencing. In case of mosaicism in leucocytes, the detection limits of Sanger sequencing for presence of variation is ~12%. The sequence was aligned to available reference sequence ENST00000544455.1¹ to detect variation using variant analysis software programs.

REFERENCES

1. ENSEMBL: <http://www.ensembl.org>.

Figure 1: Sequence chromatogram and alignment to the reference sequence showing the variation in exon 3 of the *BRCA2* gene (chr13:g.32893302del; c.156del; p.His52GlnfsTer28) detected in heterozygous condition in Ms. Nagwa Ashri Mohamed Hussien.

